IS6925A - Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns - Google Patents

Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns

Info

Publication number: IS6925A
Authority: IS; Iceland
Prior art keywords: tegafur; carboplatin; paclitaxel; uracil; tumors
Prior art date: 2001-03-06

Application number

IS6925A

Other languages

English (en)

Inventor

A. Ajani Jafferhusen

E. Benner Steven

S. Dugan Terry

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-06

Filing date

2003-08-22

Publication date

2003-08-22

2003-08-22 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2003-08-22 Publication of IS6925A publication Critical patent/IS6925A/is

Links

ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 title 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title 2
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
229930012538 Paclitaxel Natural products 0.000 title 1
190000008236 carboplatin Chemical compound 0.000 title 1
229960004562 carboplatin Drugs 0.000 title 1
239000002552 dosage form Substances 0.000 title 1
229960000304 folic acid Drugs 0.000 title 1
235000019152 folic acid Nutrition 0.000 title 1
239000011724 folic acid Substances 0.000 title 1
229960001592 paclitaxel Drugs 0.000 title 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title 1
WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 title 1
229960001674 tegafur Drugs 0.000 title 1
229940035893 uracil Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Epoxy Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

IS6925A 2001-03-06 2003-08-22 Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns IS6925A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27357701P	2001-03-06	2001-03-06
PCT/US2002/006262 WO2002076459A1 (en)	2001-03-06	2002-03-04	Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin

Publications (1)

Publication Number	Publication Date
IS6925A true IS6925A (is)	2003-08-22

Family

ID=23044526

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6925A IS6925A (is)	2001-03-06	2003-08-22	Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns

Country Status (20)

Country	Link
US (1)	US6770653B2 (is)
EP (1)	EP1368034A1 (is)
JP (1)	JP2005506294A (is)
KR (1)	KR20030081496A (is)
BR (1)	BR0207443A (is)
CA (1)	CA2439676A1 (is)
CZ (1)	CZ20032266A3 (is)
EE (1)	EE200300429A (is)
HR (1)	HRP20030801A2 (is)
HU (1)	HUP0303466A3 (is)
IL (1)	IL157357A0 (is)
IS (1)	IS6925A (is)
MX (1)	MXPA03007989A (is)
NO (1)	NO20033910L (is)
PL (1)	PL363967A1 (is)
RU (1)	RU2284184C2 (is)
SK (1)	SK10602003A3 (is)
WO (1)	WO2002076459A1 (is)
YU (1)	YU69903A (is)
ZA (1)	ZA200306541B (is)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR0115162A (pt) *	2000-11-06	2003-10-21	Pharma Mar Sa	Tratamentos antitumorais eficazes
CN1761665A (zh)	2003-03-14	2006-04-19	大鹏药品工业株式会社	抗肿瘤效果增强剂和抗肿瘤剂
WO2004087105A1 (en) *	2003-04-02	2004-10-14	Celator Pharmaceuticals, Inc.	Combination formulations of platinum agents and fluoropyrimidines
GB0312407D0 (en) *	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
AU2004291037A1 (en) *	2003-11-14	2005-06-02	Pharma Mar, S.A.	Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
KR20050099311A (ko) *	2004-04-09	2005-10-13	에이엔에이치 케어연구소(주)	주사제용 항암제 조성물
EP1827500B1 (en) *	2004-10-26	2009-05-06	Pharma Mar S.A., Sociedad Unipersonal	Pegylated liposomal doxorubicin in combination with ecteinescidin 743
ATE368461T1 (de)	2004-10-29	2007-08-15	Pharma Mar Sa	Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
KR20070114753A (ko)	2005-02-18	2007-12-04	아브락시스 바이오사이언스 인크.	치료제의 조합 및 투여 방식, 및 조합 요법
US8735394B2 (en)	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
GB0522082D0 (en) *	2005-10-31	2005-12-07	Pharma Mar Sa	Formulations
AU2008202078B2 (en) *	2007-10-10	2012-05-31	Wellkey Holdings Limited	Stability of secondary metabolite mass production through synchronized plant cell cultures
US20100267732A1 (en) *	2007-10-19	2010-10-21	Pharma Mar, S.A.	Prognostic Molecular Markers for ET-743 Treatment
EP3141245A1 (en)	2010-03-29	2017-03-15	Abraxis BioScience, LLC	Methods of treating cancer
MX2012011155A (es)	2010-03-29	2012-12-05	Abraxis Bioscience Llc	Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es)	2010-06-04	2017-04-19	Abraxis Bioscience Llc *	Metodos de tratamiento contra el cancer pancreatico.
US20180085377A1 (en) *	2015-04-22	2018-03-29	Syn-Nat Products Enterprise LLC	Co-crystal composition and its pharmaceutical use
IL265044B2 (en)	2016-08-31	2025-02-01	Fujifilm Corp	An antitumor preparation containing the substances nab-paclitaxel and 1-(2-deoxy-2-fluoro-4-thio-D-beta-arabinofurnosyl)cytosine, a kit containing these substances and their uses
RU2646450C1 (ru) *	2017-05-11	2018-03-05	Владимир Михайлович Курусин	Способ лечения предраковых и ранних стадий раковых заболеваний желудка
WO2019146130A1 (ja)	2018-01-29	2019-08-01	富士フイルム株式会社	胆道がん用抗腫瘍剤および胆道がんの処置方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5A (en) *		1836-08-10	Thomas Blanchard	Machine for mortising solid wooden shells of ships' tackle-blocks
US4328229A (en)	1978-03-29	1982-05-04	Taiho Pharmaceutical Company Limited	Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en)	1991-09-05	1996-07-09	Taiho Pharmaceutical Company, Ltd.	Antitumor potentiator and antitumor composition
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) *	1994-11-14	1999-07-06	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
RU2194541C1 (ru) *	2001-07-13	2002-12-20	Научно-исследовательский институт онкологии Томского научного центра СО РАН	Способ комбинированного лечения больных местнораспространенным раком желудка

2002
- 2002-03-04 MX MXPA03007989A patent/MXPA03007989A/es unknown
- 2002-03-04 HR HR20030801A patent/HRP20030801A2/hr not_active Application Discontinuation
- 2002-03-04 CA CA002439676A patent/CA2439676A1/en not_active Abandoned
- 2002-03-04 WO PCT/US2002/006262 patent/WO2002076459A1/en not_active Ceased
- 2002-03-04 RU RU2003129527/14A patent/RU2284184C2/ru not_active IP Right Cessation
- 2002-03-04 EP EP02713715A patent/EP1368034A1/en not_active Withdrawn
- 2002-03-04 EE EEP200300429A patent/EE200300429A/xx unknown
- 2002-03-04 JP JP2002574974A patent/JP2005506294A/ja active Pending
- 2002-03-04 BR BR0207443-5A patent/BR0207443A/pt not_active IP Right Cessation
- 2002-03-04 KR KR10-2003-7011636A patent/KR20030081496A/ko not_active Withdrawn
- 2002-03-04 CZ CZ20032266A patent/CZ20032266A3/cs unknown
- 2002-03-04 US US10/090,354 patent/US6770653B2/en not_active Expired - Fee Related
- 2002-03-04 PL PL02363967A patent/PL363967A1/xx not_active Application Discontinuation
- 2002-03-04 HU HU0303466A patent/HUP0303466A3/hu unknown
- 2002-03-04 IL IL15735702A patent/IL157357A0/xx unknown
- 2002-03-04 SK SK10602003A patent/SK10602003A3/sk not_active Application Discontinuation
- 2002-03-04 YU YU69903A patent/YU69903A/sh unknown
2003
- 2003-08-21 ZA ZA200306541A patent/ZA200306541B/xx unknown
- 2003-08-22 IS IS6925A patent/IS6925A/is unknown
- 2003-09-04 NO NO20033910A patent/NO20033910L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2005506294A (ja)	2005-03-03
EP1368034A1 (en)	2003-12-10
HUP0303466A2 (hu)	2004-01-28
SK10602003A3 (en)	2004-10-05
WO2002076459A1 (en)	2002-10-03
CZ20032266A3 (cs)	2004-02-18
YU69903A (sh)	2006-08-17
ZA200306541B (en)	2004-11-22
RU2284184C2 (ru)	2006-09-27
HUP0303466A3 (en)	2005-02-28
HRP20030801A2 (en)	2004-08-31
RU2003129527A (ru)	2005-03-10
IL157357A0 (en)	2004-02-19
EE200300429A (et)	2003-12-15
PL363967A1 (en)	2004-11-29
NO20033910L (no)	2003-10-23
US6770653B2 (en)	2004-08-03
KR20030081496A (ko)	2003-10-17
CA2439676A1 (en)	2002-10-03
BR0207443A (pt)	2004-04-06
NO20033910D0 (no)	2003-09-04
US20020173482A1 (en)	2002-11-21
MXPA03007989A (es)	2003-12-04

Publication	Publication Date	Title
IS6925A (is)	2003-08-22	Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns
WO2002062763A3 (en)	2002-10-10	Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas
WO2003080582A3 (de)	2004-12-09	Fredericamycin-derivate
WO2002085857A3 (en)	2003-01-16	Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
IL163090A (en)	2010-06-16	Nicotinamide derivates, pharmaceutical compositions comprising them and their use for manufacture of medicaments useful as p38 inhibitors
BR0312573A (pt)	2005-04-26	Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
IL164135A (en)	2011-07-31	4-anilino quinazoline derivatives as antiproliferative agents, process for their preparation, pharmaceutical compositions containing such derivatives and use thereof for the preparation of medicaments for the treatment of cancer
CY1106766T1 (el)	2012-05-23	Παραγωγα πυριδινης ως αναστολεις raf κινασης
ATE442142T1 (de)	2009-09-15	Fredericamycin-derivate als arzneimittel zur tumorbehandlung
WO2005110994A3 (en)	2006-02-02	Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2003084539A3 (en)	2004-09-02	New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
DE60318013D1 (de)	2008-01-24	N-oxid von n-phenyl-2-pyrimidinaminderivaten
ATE408601T1 (de)	2008-10-15	Fredericamycin-derivate
NO20070514L (no)	2007-03-12	Pyrrolotriazin kinase inhibitorer
EE200300475A (et)	2004-02-16	Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
ATE369355T1 (de)	2007-08-15	Pyrimidinamid derivate und deren verwendung
CY1108395T1 (el)	2014-02-12	Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων
WO2004073615A3 (en)	2005-06-16	Deazaflavin compounds and methods of use thereof
ATE336489T1 (de)	2006-09-15	Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
NO20034690L (no)	2003-10-20	Fremgangsmåte for behandling av tumorer ved administrering av tegafur, uracil, folinsyre og cyklofosfamid
HK1060518A (en)	2004-08-13	Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
DE50304524D1 (de)	2006-09-14	Arzneimittel enthaltend substituierte 2,5-diaminomethyl-1h-pyrrole
NO20060045L (no)	2006-03-01	Indolederivater med apoptoseinduserende effekt